In Vivo Safety and Toxicity Evaluation During Drug Discovery

Pharmacology Discovery Services provides preclinical safety and toxicology evaluations. Our expertise in in vivo safety and toxicology evaluations is complemented by the in vitro pharmacology and cell-based in vitro toxicity services provided by our Partner Lab, Eurofins Discovery. Together, we deliver a thorough risk profile for your drug candidates, enabling timely adjustments during critical stages of development, and minimizing potential project delays.

We offer a diverse portfolio of qualified in vivo models tailored for safety evaluations across a broad spectrum of biological systems, including the CNS, respiratory, renal, metabolic, and gastrointestinal functions, alongside non-GLP general toxicology assessments. Our approach includes using a broad panel of industry-standard outcome measures to construct an extensive toxicological profile. The integrated strategy in preclinical safety and toxicology assessment ensures a thorough evaluation of potential risks, guiding your drug development with precision and reliability.

Speak with
an expert

Publications

• Anti-HIV-1 Activity of pepRF1, a Proteolysis-Resistant CXCR4 Antagonist Derived from Dengue Virus Capsid Protein. Cadima-Couto I et al. ACS Infect. Dis. 2020 Dec;7(1):6-22. https://doi.org/10.1021/acsinfecdis.9b00507
• Optimization of Substrate‐Analogue Furin Inhibitors. Ivanova T et al. ChemMedChem. 2017 Oct; 12(23):1953-1968. https://doi.org/10.1002/cmdc.201700596